Needham Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
B.Riley Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $92
Robust CMI Drug Sales and Synergistic Commercial Strategies Bolster Buy Rating for Cytokinetics
Vertex Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $885
Eli Lilly and Co Analyst Ratings
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,117
Wolfe Research Adjusts Eli Lilly's Price Target to $1,117 From $909
Vertex Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $500 From $450, Maintains Buy Rating
Buy Rating Affirmed for Vertex Pharmaceuticals Amid Strategic Acquisition and Strong CF Franchise Outlook
Piper Sandler Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Mereo BioPharma Group Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Price Target Raised to $220.00/Share From $150.00 by Cantor Fitzgerald